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BMIAbstract Objective: The aim of this study was to assess the level of serum leptin hormone in
chronic obstructive pulmonary disease patients during acute exacerbation and in stable conditions
and also, to determine if these changes correlate with changes in the ventilatory functions.
Methods: Sixty cases were included in this prospective study (40 COPD patients and 20 age
related smokers without symptoms or signs of COPD and within normal pulmonary functions as
a control). Patients and control were divided according to their BMI into obese (BMIP 30) and
non-obese (BMI = 18.5–25). Subjects were submitted to full history taking, thorough physical
examination, plain chest X-ray, complete blood count, erythrocyte sedimentation rate, liver and
kidney functions, fasting and post prandial blood sugar, ventilatory functions, and serum leptin
level measurement.
Results: Serum leptin level (ng/ml) was signiﬁcantly higher (P< 0.001) in stable obese COPD
(mean ± SD= 23.85 ± 4.47) patients than obese controls (mean ± SD= 20.9 ± 2.7) and stable
non-obese COPD (mean ± SD= 5.63 ± 1.05) and stable non-obese COPD cases had signiﬁcantly
higher (P< 0.05) serum leptin level than non-obese controls (mean ± SD= 6.53 ± 1.19). Serum
leptin level was signiﬁcantly higher (P< 0.001) in obese COPD cases during exacerbation
(mean ± SD= 67.59 ± 9.8) than in non-obese COPD cases during exacerbationrculosis.
558 A.E. Mahmoud et al.(mean ± SD= 18.14 ± 4.15). Signiﬁcant positive correlation between serum leptin and BMI (kg/m2)
of different groups (P< 0.01) [obese control (r= 0.945), non-obese control (r= 0.970), obese
COPD in exacerbation (r= 0.812), obese COPD in stable state (r= 0.774), non-obese COPD
exacerbation (r= 0.876) and non-obese COPD in stable state (r= 0.799)].
Conclusion: Serum leptin hormone level (ng/ml) was signiﬁcantly higher in obese COPD cases
than in controls and non-obese cases and during exacerbation than in stability which indicates that
leptin plays a role in the systemic inﬂammatory process. Serum leptin hormone level positively cor-
related with BMI (kg/m2).
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease with some signiﬁcant extra pul-
monary effects that may contribute to the severity in individual
patients, its pulmonary component is characterized by airﬂow
limitation that is not fully reversible, the airﬂow limitation is
usually progressive and associated with an abnormal inﬂam-
matory response of the lung to noxious particles or gases [1].
Tobacco smoking is a common risk factor for multiple co-
morbidities, including coronary heart disease, heart failure and
lung cancer. Co-morbidities such as pulmonary artery disease
and malnutrition are directly caused by COPD. These
extrapulmonary manifestations are mostly caused by chronic
systemic inﬂammation. All of these co-morbidities potentiate
the impact of COPD on health and lead to increased hospital-
izations and healthcare costs [2–5].
Obesity is deﬁned as a body mass index (BMI) greater than
30 kg/m2; Over 1.6 billion adults worldwide are overweight, of
which 400 million are obese. The World Health Organization
predicted that 10% of the global population will be obese by
2015; In the United States of America, the annual health care
costs are 36% greater for an obese patient compared with a
patient with a normal BMI [6].
Leptin is a 167 amino acid peptide made exclusively in
adipose tissue in a wide range of animal species, including
humans. The (ob) gene encoding leptin is located on the mouse
chromosome and the human homolog of the ob gene has been
mapped to chromosome (7q31). Northern blot or RT-PCR
analysis of the messenger ribonucleic acid (mRNA) for the
ob gene showed that it was expressed only in adipose tissue
[7–9].
Aim of the work
The aim of this study was to assess the level of serum leptin
hormone in chronic obstructive pulmonary disease patients
during acute exacerbation and in stable conditions and also,
to determine if these changes correlate with changes in the
ventilatory functions.
Methods
Sixty cases were included in this prospective study (40 COPD
patients and 20 age related smokers without symptoms or signs
of COPD and within normal pulmonary functions as a
control). All COPD cases were in acute exacerbation and wereadmitted in El-Fayuom Chest hospital and Chest Department
in Benha University from October 2010 to October 2011 and
the diagnosis of COPD was established on the basis of
Global Initiative for Chronic Obstructive Lung Disease [1].
All participants were divided according to their body mass
index (BMI) values into non-obese (BMI < 25 > 18.5) and
obese (BMIP 30). Participants were classiﬁed into 4 groups:
group-1 (G1) contained 20 obese COPD cases, Group-2 (G2)
contained 20 non-obese COPD cases, control-1 (C1) contained
10 control subjects and control-2 (C2) contained 10 control
subjects.
Exclusion criteria for participants:
The presence of a co-morbidity can affect the levels of
leptin hormone in cardiovascular disease, cerebral vascular
diseases, Diabetes mellitus, arthritis, liver cirrhosis, end-stage
renal disease, Tuberculosis, bronchiectasis, malignancy and
connective tissue disorders [10].
All participants were subjected to the following:
1. Thorough history taking and clinical examination
including:
– Measuring of smoking index (number of packs/day x
number of years smoking).
– History of co-morbidities that may affect the level of the
leptin hormone as ischemic heart diseases, hypertension,
diabetes mellitus, tuberculosis, malignancy, end-stage
renal disease, rheumatoid arthritis and any systemic in-
fection or inﬂammation [10].
2. Body mass index (BMI): was calculated for all cases (the
weight in kg divided by height2).
3. Laboratory investigations: complete blood picture, erythro-
cyte sedimentation rate, fasting and 2 h post-prandial blood
glucose, kidney and liver function tests.
4. Radiological examination: plain postero-anterior and
lateral chest x-rays were done to exclude any chest lesion
if present.
5. Pulmonary function tests (spirometry): before and after
bronchodilatation using Sensor-medics V max series, 2130
Spirometer, V6200 Autobox, 6200DL. Ambient tempera-
ture and pressure were entered with the patient data (age
in years, weight in kilograms, height in centimeters and
sex) so that all results were calculated as percent of pre-
dicted (% predicted) except for FEV1/FVC. Pulmonary
functions were done pre and post bronchodilatation during
acute exacerbation of the disease and pre and post bron-
chodilatation after management of cases during stability.
6. Serum leptin hormone measurement:
Table 1 Statistical comparison of the demographic data between the studied groups.
Data Group N Range MEAN± SD t test p value Signiﬁcance
Age (years) C1 10 57–64 61.1 ± 2.07 0.092 >0.05 NS
C2 10 55–65 61.2 ± 2.74
G1 20 51–67 59.65 ± 4.47 0.388 >0.05 NS
G2 20 50–65 59.1 ± 4.48
G1 20 51–67 59.6 ± 4.47 0.967 >0.05 NS
C1 10 57–64 61.1 ± 2.07
G2 20 50–65 59.1 ± 4.48 1.353 >0.05 NS
C2 10 55–65 61.2 ± 2.74
BMI (kg/m2) C1 10 37–41 39.1 ± 1.65 35.972 <0.001 HS
C2 10 20–23 21.6±.68
G1 20 34–43 37.55 ± 3.3 24.399 <0.01 HS
G2 20 18–23 20.4 ± 1.9
G1 20 34–43 37.55 ± 3.3 1.8 >0.05 NS
C1 10 37–41 39.1 ± 1.65
G2 20 18–23 20.4 ± 1.93 1.943 >0.05 NS
C2 10 20–23 21.6±.68
S.I pack/year C1 10 60–87 76.9 ± 11.03 0.196 >0.05 NS
C2 10 64–86 76.2 ± 8.24
G1 20 65–100 80.2 ± 12.2 0.902 >0.05 NS
G2 20 62–90 76.9 ± 10.9
G1 20 65–100 80.2 ± 12.2 0.719 >0.05 NS
C1 10 60–87 76.9 ± 11.03
G2 20 62–90 76.9 ± 10.89 0.184 >0.05 NS
C2 10 64–86 76.2 ± 8.24
G1 = obese COPD, G2 = non-obese COPD, C1 = Obese controls, C2 = non-obese control, HS = highly signiﬁcant, S = signiﬁcant,
NS = non-signiﬁcant.
Table 2 Statistical comparison of the pulmonary function data between the studied obese and non-obese COPD cases during stable
state and exacerbation.
Parameter Group Range Mean ± SD P value Signiﬁcance
FVC% predicted G1 Stable 70–78 74.55 ± 2.5 >0.05 NS
G2 Stable 67–81 75.7 ± 3.46
G1 Exacerbation 77–81 79.5 ± 1.35 <0.05 S
G2 Exacerbation 83–88 85.9 ± 1.3
FEV1% predicted G1 Stable 31–43 36.1 ± 6.33 >0.05 NS
G2 Stable 24–48 38.1 ± 6.85
G1 Exacerbation 50–56 53.45 ± 1.8 <0.05 S
G2 Exacerbation 57–63 60.5 ± 1.8
FEV1/FVC G1 Stable 0.32–0.66 0.47 ± 0.08 >0.05 NS
G2 Stable 0.34–0.61 0.49 ± 0.07
G1 Exacerbation 0.62–0.65 0.62 ± 0.01
< 0.05
S
G2 Exacerbation 0.67–0.72 0.69 ± 0.01
FEF25–75% G1 Stable 17–30 23.4 ± 4.03 >0.05 NS
G2 Stable 20–34 24.85 ± 3.6
G1 Exacerbation 53–62 58.1 ± 3.1 >0.05 NS
G2 Exacerbation 53–63 58.7 ± 3.5
G1 = obese COPD, G2 = non-obese COPD, HS = highly signiﬁcant, S = signiﬁcant, NS = non-signiﬁcant.
There were non-signiﬁcantly statistical differences between obese and non-obese COPD cases during stability regarding FVC% Predicted,
FEV1% Predicted, FEV1/FVC and FEF25–75%. There were signiﬁcantly statistical differences between obese and non-obese COPD cases
during exacerbation regarding FVC% Predicted, FEV1% Predicted and FEV1/FVC.
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The leptin hormone level was measured twice in all COPD
patients [in acute exacerbation (AECOPD) and after stability]and once in all control subjects. All samples were collected at
9 AM and all patients were in fasting state for at least 8 h.
Four–ﬁve milli liter of blood was collected into an
Table 3 Statistical comparison in serum leptin (ng/ml) in obese and non-obese COPD cases during exacerbation and stability.
Group State Range Mean ± SD P value Signiﬁcance
G1 Exacerbation 49–83 64.59 ± 9.8 <0.001 HS
Stable 17–31 23.85 ± 4.47
G2 Exacerbation 11.6–29 11.6–29 <0.001 HS
Stable 4.1–7.4 4.1–7.4
G1 = obese COPD, G2 = non-obese COPD, HS = highly signiﬁcant
There was a statistically highly signiﬁcant difference in leptin concentration during acute exacerbation and during stability in obese COPD cases
and a highly signiﬁcant difference in leptin concentration during acute exacerbation and during stability in non-obese COPD cases.
560 A.E. Mahmoud et al.appropriately labeled tube and all samples centrifuged and
carefully the layer was removed then the serum samples were
stored at (70) degree till analyzed.
Principles of the test:
Quantitative analysis of the serum leptin level was done
using an enzyme immunoassay. The approximate leptin
concentration in the patient sample was calculated (leptin
Titer in ng/ml) and a Reference value of 3.8 ng/ml [range (2–
5.6 ng/ml) in normal weight non-obese male patient] was
determined.
Serum leptin measurement procedure:
The kit components:
– Anti leptin monoclonal antibody coated Microwell
plate-break apart wells.
– Monoclonal anti leptin antibody conjugated to biotin in a
protein based buffer with a non mercury preservative in a
bottle 10 ml.
– Streptavidin conjugated to horseradish peroxidase in
protein based buffer with a non mercury preservative in a
bottle 0.4 ml.
– Six bottles of leptin calibrators containing leptin in a
protein based buffer with a non mercury preservative.
– One bottle of control solution containing leptin in a protein
based buffer with non mercury preservative.
– One bottle of wash buffer concentrate containing buffer
with non-ionic detergent and non mercury preservative.
– One bottle of assay buffer containing protein based buffer
with non mercury preservative.
– One bottle of TMB substrate (tetramethylbenzidine) and
hydrogen peroxide in non DMF or DMSO containing
buffer.
– One bottle of stopping solution containing sulfuric acid.
The procedure:
– Working solution of streptavidin HRP conjugate and wash
buffer was prepared.
– 20 ll of each calibrator, control and serum sample was
pipetted into correspondingly labeled wells in duplicate.
– 80 ll of the monoclonal anti-leptin-biotin conjugate was
pipetted into each well.
– Incubated on a shaker for 1 h at room temperature.
– The wells were washed 3 times with prepared wash buffer.
– 100 ll of prepared streptavidin HRP conjugate was pipetted
into each well.
– Incubated on a plate shaker for 30 min at room
temperature.– The wells were washed 3 times with prepared wash buffer.
– 100 ll of TMB substrate was pipetted into each well.
– Incubated on a plate shaker for 15 min at room
temperature.
– 50 ll of stopping solution was pipetted into each well.
– The plate was read on the Microwell plate reader at 450 nm
in 20 min.
Statistical analysis
Results are given as mean ± SD. Differences between groups
were statistically analyzed using an unpaired Student’s t test.
In the patients with leptin values below the detection limit
(0.25 ng/ml); the value 0.25 ng/ml is used in the analysis.
After curve estimation, linear, exponential or logarithmic
Pearson product moment correlation will be calculated. After
the simple correlations, a regression model will be ﬁtted to
the data to select the variables that contributed to the
explained variation in plasma leptin concentration.
Signiﬁcance will be determined at the 5% level. Data were ana-
lyzed using SPSS (Statistical Package for the Social Sciences,
version 14.0 for Windows).
Results and discussion
Researchers have speculated that a potential link between obe-
sity and COPD subsists since low BMI and weight loss are
associated with increased mortality in patients suffering from
COPD [11].
The aim of this study was to assess the level of serum leptin
hormone in chronic obstructive pulmonary disease patients
during acute exacerbation and in stable conditions and also,
to determine if these changes correlate with changes in the
ventilatory functions.
Regarding the statistical comparison in demographic data
between all groups in this study there were no statistically sig-
niﬁcant differences in different values except BMI between
obese and non-obese groups (Table 1).
In this study pre and post-bronchodilator spirometry was
done among 40 patients known to have COPD during exacer-
bation and stability and showed partial reversibility in the
FEV1% predicted (less than 12%) conﬁrming the diagnosis
of COPD.
Regarding pulmonary function parameters, there was no
statistically signiﬁcant difference between obese and non-obese
COPD cases during stability regarding FVC% predicted,
Table 4 Statistical comparison of serum leptin (ng/ml) between obese and non-obese COPD cases during exacerbation and during
stability.
Group Range Mean ± SD P value Signiﬁcance
Exacerbation G1 49–83 64.59 ± 9.8 <0.001 HS
G2 11.6–29 18.14 ± 4.1
Stability G1 17–31 23.85 ± 4.47 <0.001 HS
G2 4.1–7 5.63 ± 1.05
G1 = obese COPD, G2 = non-obese COPD, C1 = obese controls, C2 = non-obese control, HS = highly signiﬁcant, S = signiﬁcant,
NS = non-signiﬁcant.
There was a statistically highly signiﬁcant difference in serum leptin concentration between obese and non-obese COPD cases during acute
exacerbation and stability.
Table 5 Serum leptin (ng/ml) in obese COPD cases during exacerbation and in stable state in comparison with obese control cases.
State Group N Range MEAN± SD P. value Signiﬁcance
Exacerbation G1 20 49–83 67.59 ± 9.8 <0.001 HS
C1 10 16–25 20.9 ± 2.7
Stable G1 20 17–31 23.8 ± 4.47 <0.05 S
C1 10 16–25 20.9 ± 2.7
G1 = obese COPD, C1 = obese controls, HS = highly signiﬁcant, S = signiﬁcant.
There was a statistically highly signiﬁcant difference in serum leptin concentration (ng/ml) in obese COPD cases during exacerbation and obese
control cases and a statistically signiﬁcant difference in serum leptin concentration in obese COPD cases during stability and obese control
cases.
Table 6 Serum leptin (ng/ml) in non-obese COPD cases during exacerbation and in stable state in comparison with non-obese control
cases.
State Group N Range Mean ± SD P value Signiﬁcance
Exacerbation G2 20 11.6–29 18.14 ± 4.15 <0.001 HS
C2 10 4.7–8.12 6.53 ± 1.19
Stability G2 20 4.1–7.4 5.63 ± 1.05 <0.05 S
C2 10 4.7–8.12 6.53 ± 1.19
G1 = obese COPD, G2 = non-obese COPD, C1 = Obese controls, C2 = non-obese control, HS = highly signiﬁcant, S = signiﬁcant,
NS = non-signiﬁcant.
There was a statistically highly signiﬁcant difference in serum leptin concentration between non-obese COPD cases during exacerbation and
non-obese control cases and also a statistically signiﬁcant difference between non-obese COPD cases during stability and non-obese control
cases.
Leptin hormone in obese and non-obese cases of COPD 561FEV1% predicted, FEV1/FVC and FEF25–75%. There were
statistically signiﬁcant differences between obese and non-
obese COPD cases during exacerbation regarding FVC% pre-
dicted, FEV1% predicted and FEV1/FVC (Table 2).
Similar results were reported by [12] who studied 97 men
aged 67–78 y with body mass index (BMI; in kg/m2) ranging
from 19.8 to 37.1. Body composition was evaluated by using
dual-energy X-ray absorptiometry and fat distribution was
evaluated by using waist and hip circumferences, waist-to-hip
ratio, and sagittal abdominal diameter (SAD). Spirometry
was done in all subjects and the distance walked by each sub-
ject during a 6-min walking test was evaluated as leg strength
and found a signiﬁcant negative correlation between adiposity,
fat distribution indexes, forced vital capacity (FVC), and
forced expiratory volume in 1 s (FEV1).This was also in agreement with work done by [13] who
examined the combined effects of obesity and COPD on
dyspnea and exercise tolerance by comparing dyspnea intensity
ratings and ventilatory responses (breathing pattern, operating
lung volumes and gas exchange) during symptom-limited
incremental cycle exercise in well characterized groups of 18
obese (BMI = 35 ± 4 kg/m2; mean ± SD) and 18 normal-
weight (BMI = 22 ± 2 kg/m2) patients with moderate to
severe COPD. Groups were well matched for FEV1 (mean
49% predicted) and diffusing capacity (means > 70%
predicted) but resting lung hyperinﬂation [end-expiratory lung
volume (EELV)] was signiﬁcantly reduced in association with
increasing BMI (p< 0.005).
Regarding the serum leptin level (Tables 3–6), there was a
statistically high signiﬁcant difference in leptin concentration
Table 7 Correlation between serum leptin (ng/ml) and body
mass index (kg/m2) in the different studied groups.
Group R p value Signiﬁcance
C1 0.945 <0.001 HS
C2 0.970 <0.001 HS
G1 Exacerbation 0.812 <0.001 HS
G1 Stable 0.774 <0.001 HS
G2 Exacerbation 0.876 <0.001 HS
G2 Stable 0.799 <0.001 HS
G1 = obese COPD, G2 = non-obese COPD, C1 = obese con-
trols, C2 = non-obese control, HS = highly signiﬁcant.
562 A.E. Mahmoud et al.during acute exacerbation (mean ± SD= 64.59 ± 9.8 ng/ml)
and during stability (mean ± SD= 23.85 ± 4.47 ng/ml) in
obese COPD cases and a high signiﬁcant difference in leptin
concentration during acute exacerbation (mean ± SD=
18.14 ± 4.1 ng/ml) and during stability (mean ± SD=
5.63 ± 1.05 ng/ml) in non-obese COPD cases. Both compar-
isons indicated that the level of serum leptin hormone (ng/
ml) elevated during COPD exacerbation than during stability.
There was a statistically high signiﬁcant difference in serum
leptin concentration between obese and non-obese COPD
cases during acute exacerbation and stability. There was a sta-
tistically high signiﬁcant difference in serum leptin concentra-
tion (ng/ml) in obese COPD cases during exacerbation and
obese control cases and a statistically signiﬁcant difference in
serum leptin concentration in obese COPD cases during stabil-
ity and obese control cases. There was a statistically high sig-
niﬁcant difference in serum leptin concentration between
non-obese COPD cases during exacerbation and non-obese
control cases and also a statistically signiﬁcant difference
between non-obese COPD cases during stability and non-
obese control cases.
This ﬁnding was in agreement with work done by Calikoglu
et al. [14] that reported malnourished patients experiencing
exacerbation, exhibit signiﬁcantly higher leptin levels, com-
pared to normal-weight stable COPD patients, an observation
not replicated when compared to malnourished stable COPD
patients.
Also in agreement with a study done by Kythreotis et al.
[15] and measures plasma leptin and insulin-like growth factor
I levels during acute exacerbations of chronic obstructive pul-
monary disease and indicated that leptin values were signiﬁ-
cantly elevated in COPD patients during acute exacerbation
versus controls and leptin concentrations gradually decreased
throughout the exacerbation, but, remain signiﬁcantly elevated
during hospitalization. The normal feedback regulation of lep-
tin preserved on day 7 of the exacerbation, although dissocia-
tion has been reported on day 1, is possibly due to a temporary
dysfunction related to the event.
Similar results were also obtained by Creutzberg et al. [16]
who indicated that the disturbances in leptin metabolism were
related to energy imbalance during acute exacerbations of
chronic obstructive pulmonary disease and indicated that there
was transient elevation in serum leptin concentration (ng/ml)
during acute exacerbation.
On the other hand, these results were not matched with the
results of the work done by Yang et al. [17] who measured the
role of serum leptin hormone and tumor necrosis factor-alpha
in malnutrition of male chronic obstructive pulmonary disease
patients and indicated that there was no statistically signiﬁcant
difference in serum leptin levels between COPD patients with-
out malnutrition during acute exacerbation, COPD patients
without malnutrition during stable state and controls.
These results were also in agreement with work done by
Considine et al. [18] that measured serum immunoreactive-lep-
tin concentrations in normal-weight and obese humans and
indicated that leptin levels increase in parallel to the volume
of adipose stores, suggesting that leptin increases exponentially
with increasing fat mass.
Similar results were also obtained by work done by Maffei
et al. [19] who measured leptin levels in human and rodent and
measurement of plasma leptin and ob RNA in obese and
weight-reduced subjects indicates that Plasma leptinconcentration correlates with body fat content and is usually
increased in obese subjects. This suggests that human obesity
is generally associated with insensitivity to leptin.
Similar results were also obtained by work done by
Creutzberg et al. [16] who measured the disturbances in leptin
metabolism related to energy imbalance during acute
exacerbations of chronic obstructive pulmonary disease and
indicated that there was transient elevation in serum leptin
concentration (ng/ml) during acute exacerbation.
However, our results were not matched with the results of
the work done by Yang et al. [17] who measured the role of
serum leptin hormone and tumor necrosis factor-alpha in
malnutrition of male chronic obstructive pulmonary disease
patients and indicated that there was a statistically non-signiﬁ-
cant difference in serum leptin levels (ng/ml) between COPD
patients without malnutrition during acute exacerbation,
COPD patients without malnutrition during stable state and
controls.
All these ﬁndings demonstrated that serum leptin hormone
increased in obese subjects than non-obese subjects as it is a
hormone secreted from adipose tissue and elevated in obese
and non-obese during exacerbation than in obese and non-
obese controls and also elevated in obese COPD cases during
stability than in obese controls as it is an inﬂammatory marker
increased during systemic inﬂammation; but it decreases in
non-obese COPD cases than in non-obese controls.
This was in agreement with work done by Takabatake et al.
[20] who investigated serum leptin levels, along with circulating
tumor necrosis factor (TNF ) and soluble TNF receptor
(sTNF-R55 and -R75) levels, in 31 patients with COPD and
15 age-matched healthy controls. The body mass index
(BMI) and percent body fat (%fat) were signiﬁcantly lower
in the COPD patients than in the healthy controls and serum
leptin levels were signiﬁcantly lower in the COPD patients than
in the healthy controls.
A study done by Figen et al. [21] who measured plasma
leptin concentrations in thirty-two patients with COPD (all
males) with stable chronic obstructive pulmonary disease indi-
cated that patients with COPD had signiﬁcantly lower leptin,
albumin and CKr levels than did the control subjects. COPD
patients also had decreased arterial PO2, and increased arterial
PCO2 values. The levels of FEV1 (% predicted) and FVC (%
predicted) were signiﬁcantly lower in COPD patients than in
healthy controls. Serum TNF-a level in COPD patients was
signiﬁcantly higher than those in the healthy controls.
In the present study the correlations between serum leptin
concentration (ng/ml) and pulmonary function tests in obese
Table 8 Correlation between change in serum leptin (ng/ml)
and change in P.F.T from acute exacerbation to stability in
obese COPD cases.
Parameter R p value Signiﬁcance
FVC% predicted 0.191 >0.05 NS
FEV1% predicted 0.523 >0.05 NS
FEV1/FVC 0.541 >0.05 NS
FEF25–75%%predicted 0.135 >0.05 NS
NS = non-signiﬁcant.
Table 10 Correlation between BMI (kg/m2) and pulmonary
function tests in obese controls.
Parameter r p value SIG
FVC% predicted 0.830 <0.001 HS
FEV1% predicted 0.664 <0.05 S
FEV1/FVC 0.245 >0.05 NS
FEF25–75%%predicted 0.295 >0.05 NS
Leptin hormone in obese and non-obese cases of COPD 563control subjects were done as shown in Table 10 and indicated
that there was a statistically non-signiﬁcant positive correla-
tion between BMI (kg/m2) and FEV1/FVC-L (r= 0.245 and
p> 0.05), FEF25–75% predicted (r= 0.259 and p> 0.05)
and signiﬁcant negative correlation with FEV1% predicted
(r= 0.664 and p< 0.05) and highly signiﬁcant negative
correlation with FVC% predicted (r= 0.830 and p< 0.01).
A correlation between BMI (kg/m2) and pulmonary
function tests in non-obese controls was done and indicated
in Table 11 and showed that there was a statistically non-
signiﬁcant negative correlation between BMI (kg/m2) and
FVC% predicted (r= 0.128 and p> 0.05) and FEF25–
75% predicted (r= 0.391 and p> 0.05), signiﬁcant negative
correlation with FEV1/FVC L (r= 0.714 and p< 0.05) and
high signiﬁcant negative correlation with FEV1% predicted
(r= 0.916 and p< 0.001).
These ﬁndings were in agreement with study done by
Santana et al. [12] who measured the relation between body
composition, fat distribution, and lung function in elderly
men in 97 men aged 67–78 years with body mass indexes
(BMIs; in kg/m2) ranging from 19.8 to 37.1 and body
composition was evaluated by using dual-energy X-ray
absorptiometry and fat distribution was evaluated by using
waist and hip circumferences, waist-to-hip ratio, and sagittal
abdominal diameter (SAD). Spirometry was done in all sub-
jects and the distance walked by each subject during a 6-min
walking test was evaluated as leg strength and indicated that
there was a signiﬁcant negative correlation between adiposity,
fat distribution indexes, forced vital capacity (FVC), and
forced expiratory volume in 1 s (FEV1).
These results also were in agreement with work by Lazarus
et al. [22] who measured the effects of obesity and fat dis-
tribution on ventilatory function showed that the ratio of
abdominal circumference to hip breadth and sub-scapular
skin-fold thickness was negatively associated with FVC%
predicted.Table 9 Correlation between change in level of serum leptin
(ng/ml) and change in P.F.T from acute exacerbation to
stability in non-obese COPD cases.
Parameter r p value Signiﬁcance
FVC% predicted 0.176 >0.05 NS
FEV1% predicted 0.009 >0.05 NS
FEV1/FVC 0.057 >0.05 NS
FEF25–75%%predicted 0.129 >0.05 NS
NS = non-signiﬁcant.In the present study, we measured the correlation between
the change of serum leptin hormone concentration (which is
serum leptin in ng/ml during exacerbation – serum leptin in
ng/ml during stable state) and changes in the pulmonary
function tests (which is pulmonary function value during
exacerbation – pulmonary function value during stable state)
in obese COPD and non-obese COPD patients.
In obese COPD cases as shown in Table 8 a signiﬁcant
negative correlation was found between change in serum leptin
(ng/ml) and change in pulmonary function parameters [change
in FEV1% predicted (r= 0.523 and p< 0.05) and change in
FEV1/FVC L (r= 0.541 p< 0.05)] and non-signiﬁcant
negative correlation [change in FEF25–75% predicted
(r= 0.135 and p> 0.05)] and non-signiﬁcant positive
correlation [change in FVC% predicted (r= 0.191 and
p> 0.05)].
In non-obese COPD cases as shown in Table 9 there was no
correlation between change in serum leptin (ng/ml) and change
in pulmonary functions parameters [FVC% predicted
(r= 0.176 and p> 0.05), FEV1% predicted (r= 0.009
and p> 0.05), FEF25–75% predicted (r= 0.129 and
p> 0.05), FEV1/FVC L (r= 0.057 and p> 0.05)].
Little or no researches were found that study the correla-
tion between change in leptin concentration and change in
PFT.
In this study, correlation between serum leptin (ng/ml) and
body mass index (kg/m2) in the different studied groups was
done and shown in Table 7 and demonstrated that there was
a highly signiﬁcant positive correlation between leptin (ng/
ml) and BMI (kg/m2) of different groups (P< 0.01) and in
obese control (r= 0.945), non-obese control (r= 0.970),
obese COPD in exacerbation (r= 0.812), obese COPD in
stable state (r= 0.774), non-obese COPD exacerbation
(r= 0.876) and non-obese COPD in stable state (r= 0.799).
The results in Table 7 demonstrated that there was direct
proportion between BMI (kg/m2) and leptin levels (ng/ml)
and that leptin increased by increasing BMI and vice versa,
and it was also increased during exacerbation than during
the stable state but still higher in COPD during stability than
in control obese.
This indicates that leptin hormone plays a role in systemic
and local inﬂammatory process in COPD during acute exacer-
bation and in stable state.
These results were in agreement with a study done by
Cooper et al. [23] who measured serum leptin levels in obese
males during over and underfeeding in eight obese (BMI 30–
40 kg/m2), but otherwise healthy, males aged 19–42 who
participated in this study. Subjects were normo-lipemic
(cholesterol < 2 g/l, triglycerides < 1.55 g/l), and had normal
thyroid function as determined by thyroid-stimulating hor-
mone levels (0.4–3.6 mU/l). Due to the large volume of blood
Table 11 Correlation between BMI (kg/m2) and pulmonary
function tests in non-obese controls.
Parameter R p value SIG
FVC% predicted 0.128 >0.05 NS
FEV1% predicted 0.916 <0.001 HS
FEV1/FVC 0.714 <0.05 S
FEF25–75%%predicted 0.391 >0.05 NS
564 A.E. Mahmoud et al.being drawn, inclusion criteria included normal iron stores as
determined by serum iron (0.5–1.6 mg/l) and serum ferritin
(15–200 lg/l), and normal total iron binding capacity (2.5–
4.0 mg/l) in conjunction with normal hemoglobin (135–175 g/l).
Exclusion criteria included a history of metabolic disease, use
of prescription medication or over-the-counter substances such
as melatonin. Subjects who exercised regularly or did not eat
three meals a day (including breakfast or an early morning
meal) were also excluded. The study was approved by the
institutional review board at the University of Chicago and
all subjects provided written informed consent. The study
was performed at the Clinical Research Center at the
University of Chicago Hospital; and indicated that during
the initial eucaloric or baseline period, the serum leptin level
averaged 6.0 ± 1.1 ng/ml for the underfeeding treatment
group and 15.5 ± 2.5 ng/ml for the overfeeding treatment
group. As expected, these leptin levels correlated with body
weight (r= 0.91, P= 0.01 and r= 0.96, P= 0.01), percent
body fat (r= 0.84, P= 0.01 and r= 0.79, P= 0.02), and
trended with BMI (r= 0.62, P= 0.08 and r= 0.69,
P= 0.06) and fat mass (r= 0.57, P= 0.18 and r= 0.50,
P= 0.16), for treatment groups, respectively.
These results were also in agreement with work done by
Lazzer et al. [24] who investigated leptin changes in 26 obese
adolescents (12 boys and 14 girls) during and after a 9-month
weight-reduction program in a specialized institution with
lifestyle education, moderate energy restriction and regular
physical activity, followed by a 4-month period at home.
After 9 months, the adolescents had lost 19% body weight
and 41.3% fat mass. At the same time, plasma leptin concen-
tration was 70% lower. After the subjects had returned home
for four months, leptin rose to an intermediate level in the 10
adolescents who had regained some of the body weight they
had lost.
Similar results were reported by a work done by Ram et al.
[25]who investigated 23 obese patients (8 males, 15 females)
who had undergone laparoscopic adjustable gastric banding
surgery to achieve weight loss, their body mass index was
reduced by 33% while the levels of circulating leptin declined
by 52%. Leptin levels strongly and persistently correlated with
body mass index (BMI) during the study and, compared to
insulin, leptin showed the most signiﬁcant and persistent
correlation with BMI.
In the work done by Krommidas et al. [26] who investigated
plasma leptin, adiponectin and their ratio (L/A ratio) in acute
exacerbations of COPD and to study possible associations
with inﬂammatory biomarkers and indicated that all systemic
inﬂammatory biomarkers, leptin and L/A ratio were elevated
during admission compared to resolution and stable phase
(mean L/A ratio 2.6 vs. 1.57 vs. 1.22, respectively;
p< 0.0001), whereas adiponectin was elevated at resolutioncompared to admission. Log leptin, adiponectin and L/A ratio
were signiﬁcantly associated with variables of systemic inﬂam-
mation, after proper adjustments, both on admission and in
stable condition.
Leptin and Leptin-receptor expressing cells in normal
subjects, smokers without COPD and COPD subjects were
investigated by Bruno et al. [27] concluded that leptin
expression increased in bronchial mucosa of chronic obstruc-
tive pulmonary disease patients, associated with airway
inﬂammation and airﬂow obstruction.
Conclusion
Serum leptin hormone level (ng/ml) was signiﬁcantly higher in
COPD cases than in controls, signiﬁcantly higher in obese than
non-obese cases during exacerbation and in stable state and
signiﬁcantly higher in COPD cases during exacerbation than
during stable state which indicates that leptin plays a role in
systemic inﬂammatory process. Serum leptin hormone level
(ng/ml) correlated positively with BMI (kg/m2) and a negative
correlation was found between the change in serum leptin (ng/ml)
and the change in some pulmonary function parameters
(FEV1% predicted and FEV1/FVC).
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Hospitals, Benha, Egypt.
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